Constitutively activated ERK sensitizes cancer cells to doxorubicin: Involvement of p53-EGFR-ERK pathway
- 131 Downloads
The tumour suppressor gene p53 is mutated in approximately 50% of the human cancers. p53 is involved in genotoxic stress-induced cellular responses. The role of EGFR and ERK in DNA-damage-induced apoptosis is well known. We investigated the involvement of activation of ERK signalling as a consequence of non-functional p53, in sensitivity of cells to doxorubicin. We performed cell survival assays in cancer cell lines with varying p53 status: MCF-7 (wild-type p53, WTp53), MDA MB-468 (mutant p53, MUTp53), H1299 (absence of p53, NULLp53) and an isogenic cell line MCF-7As (WTp53 abrogated). Our results indicate that enhanced chemosensitivity of cells lacking wild-type p53 function is because of elevated levels of EGFR which activates ERK. Additionally, we noted that independent of p53 status, pERK contributes to doxorubicin-induced cell death.
KeywordsDoxorubicin EGFR ERK p53
The authors thank Dr SC Mande, Director, NCCS, Pune, and Dr GC Mishra, former Director, NCCS, Pune, for their support and encouragement in carrying out this work. RK and SS thank the University Grants Commission (UGC), RRC and SC thank the Council for Scientific and Industrial Research (CSIR), AKA thanks the Indian Council of Medical Research (ICMR), India, for research fellowships. This work was supported in part by intramural funding from National Centre for Cell Science (NCCS), Department of Biotechnology (DBT), India. The funding agencies had no involvement in study design, data collection, interpretation and analysis, decision to publish or writing of the manuscript.
Work described in this paper is a part of thesis submitted by RK in 2010 to University of Pune, Pune.
- Donato NJ, Perez M, Kang H, et al. 2000 EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity. Clin. Cancer Res. 1 193–202Google Scholar
- Dong P, Xu Z, Jia N, et al. 2009 Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. Mol. Cancer. 8 103Google Scholar
- Fernández CL, Oakman C, Falagan LP, et al. 2012 Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res. 14 R70CrossRefGoogle Scholar
- Garcia R, Franklin RA and McCubrey JA 2006 Cell death of MCF-7 human breast cancer cells induced by EGFR activation in the absence of othergrowth factors. Cell Cycle 16 1840–1846Google Scholar
- Hoshino R, Tanimura S, Watanabe K, et al. 2001 Blockade of the extracellular signal-regulated kinase pathway induces marked G1 cell cycle arrest and apoptosis in tumor cells in which the pathway is constitutively activated: up-regulation of p27(Kip1). J. Biol. Chem. 276 2686–2692Google Scholar
- Maruthampu M, Watkins J, Noor AM, et al. 2016 Economic downturns, universal health coverage, and cancer mortality in high-income and middle-income countries 1990-2010: a longitudinal analysis. Lancet 388 684–695Google Scholar
- Moerkens M, Zhang Y, Wester L, et al. 2014 Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogenreceptor α signalling and results in tamoxifen insensitive proliferation. BMC Cancer 14 383Google Scholar
- Oden-Gangloff A, Di Fiore F, Bibeau F, et al. 2009 TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br. J. Cancer. 100 1330–1335Google Scholar